A Phase 3 interventional study of evolocumab and placebo in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Amgen. Terminated at 31 sites in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 21st largest by enrollment, is the only one that started in 2019, is one of 22 in phase 3, and was the 30th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 259 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 21st largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2019, is one of 22 in phase 3, and was the 34th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to learn more about evolocumab in Chinese people with primary hypercholesterolemia or mixed dyslipidemia. This study will see if evolocumab will reduce low density lipoprotein cholesterol (LDL-C) in Chinese people who are also taking a certain type of lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side effects.
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled study of evolocumab in Chinese participants with hypercholesterolemia and mixed dyslipidemia. Participants who have signed the informed consent form (ICF) will have fasting lipids measured and all inclusion and exclusion criteria assessed. All eligible participants must be taking a maximum appropriate dose of an approved statin, not requiring up titration. Participants should maintain their current diet and exercise regimen.
Treatment and follow-up period will be 12 weeks with an additional phone call or other participant contact at week 14 for those receiving investigational product every 2 weeks (Q2W). The end of study (EOS) for participants on once monthly (QM) investigational product is at the week 12 visit, which must be at least 30 days post last dose of investigational product.
Evolocumab or placebo will be administered by self-injection under the skin at the study site or in an appropriate non-clinic setting (e.g., at home) by spring based prefilled auto injector/pen (AI/Pen). Participants must tolerate an injection of placebo with a prefilled auto injector/pen device to be used during the study prior to randomization.
Participants will be randomly added to 1 of 4 groups using a 2:2:1:1 ratio:
evolocumab 140 mg Q2W (86 participants total) evolocumab 420 mg QM (86 participants total) placebo Q2W (44 participants total) placebo QM (43 participants total). The dose frequencies of Q2W and QM will not be blinded but the identity of investigational product evolocumab or placebo will be blinded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject meets at least 1 of the following criteria for high/very high cardiovascular (CV) risk:
OR
Subject does not meet high/very high CV risk criteria but fasting LDL-C as determined by central laboratory at screening ≥ 130 mg/dl
Exclusion Criteria:
Female subject of not willing to use an acceptable method(s) of effective during treatment with investigational product and for an additional 15 weeks after the end of treatment with investigational product. Female subjects of non-childbearing potential who are not required to use contraception during the study and include those who have had a:
ii. Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
Acceptable methods of effective birth control include:
2 barrier methods (each partner must use 1 barrier method) the male uses a condom and the female must choose either a diaphragm, OR cervical cap, OR contraceptive sponge with spermicide. If spermicide is not commercially available in the country or region, the 2 barrier method without spermicide is acceptable. (A female condom is not an option due to the risk of tearing when both partners use a condom.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo subcutaneous (SC) Q2W for 12 weeks
Drug: placebo
Placebo SC QM for 12 weeks
Drug: placebo
Evolocumab 140 mg SC Q2W for 12 weeks
Drug: evolocumab
Evolocumab 420 mg SC QM for 12 weeks
Drug: evolocumab
Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
Also known as: Repatha; AMG 145
Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 12
Change From Baseline in LDL-C: Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 12
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Week 12
Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Percent Change From Baseline in ApoB at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Percent Change From Baseline in Total Cholesterol at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline and Week 12
Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12
Percentage of participants who were below the target LDL-C of 70 mg/dL (1.8 mmol/L) based on the mean LDL-C data collected at weeks 10 and 12.
Time frame: Weeks 10 and 12
Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
Time frame: Week 12
Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 12
Percentage of participants who had LDL-C response (50% reduction of LDL-C from baseline) based on the mean LDL-C using the data collected at weeks 10 and 12.
Time frame: Baseline, Weeks 10 and 12
Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12
LDL-C Response is defined as a 50% reduction of LDL-C from Baseline.
Time frame: Baseline and Week 12
Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Percent Change From Baseline in Lp(a) at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline and Week 12
Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline and Week 12
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline and Week 12
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline, Weeks 10 and 12
Percent Change From Baseline in VLDL-C at Week 12
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
Time frame: Baseline and Week 12
Participants were enrolled at 31 research centers in China from 09 May 2019 to 20 January 2020.
| Milestone | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Started | 42 | 41 | 79 | 80 |
| Randomized and treated | 41 | 41 | 79 | 80 |
| Completed | 40 | 41 | 79 | 80 |
| Not completed | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Decision by sponsor | 1 | 0 | 0 | 0 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12 | 1.88 ± 3.72 | -68.86 ± 3.27 | -0.36 ± 3.78 | -70.10 ± 3.21 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12 | 2.48 ± 4.18 | -68.39 ± 3.55 | 2.72 ± 4.25 | -63.09 ± 3.42 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| mg/dL | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C: Mean of Weeks 10 and 12 | -0.6 ± 5.4 | -77.1 ± 4.8 | -5.8 ± 5.8 | -83.0 ± 5.0 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| mg/dL | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -0.8 ± 5.8 | -76.7 ± 5.1 | -2.1 ± 6.1 | -75.1 ± 5.0 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12 | 2.36 ± 3.52 | -58.84 ± 3.10 | -0.06 ± 3.30 | -62.20 ± 2.81 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | 3.86 ± 3.85 | -57.59 ± 3.30 | 1.78 ± 3.70 | -54.86 ± 2.99 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12 | 1.80 ± 3.17 | -54.45 ± 2.79 | 0.07 ± 3.00 | -56.93 ± 2.54 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in ApoB at Week 12 | 2.53 ± 3.55 | -53.16 ± 3.03 | 1.20 ± 3.51 | -50.01 ± 2.77 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12 | 1.32 ± 2.74 | -41.42 ± 2.42 | -0.09 ± 2.68 | -44.39 ± 2.28 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Placebo 420 mg SC QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 12 | 2.69 ± 2.99 | -40.36 ± 2.57 | 1.17 ± 2.96 | -39.25 ± 2.40 |
Percentage of participants who were below the target LDL-C of 70 mg/dL (1.8 mmol/L) based on the mean LDL-C data collected at weeks 10 and 12.
| percentage of participants | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12 | 2.7 (0.5 to 13.8) | 89.9 (80.5 to 95.0) | 5.7 (1.6 to 18.6) | 97.2 (90.3 to 99.2) |
| percentage of participants | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12 | 0.0 (0.0 to 10.2) | 90.6 (81.0 to 95.6) | 3.7 (0.7 to 18.3) | 89.4 (79.7 to 94.8) |
Percentage of participants who had LDL-C response (50% reduction of LDL-C from baseline) based on the mean LDL-C using the data collected at weeks 10 and 12.
| percentage of participants | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 12 | 0.0 (0.0 to 9.4) | 87.0 (77.0 to 93.0) | 5.7 (1.6 to 18.6) | 94.4 (86.4 to 97.8) |
LDL-C Response is defined as a 50% reduction of LDL-C from Baseline.
| percentage of participants | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12 | 0.0 (0.0 to 10.2) | 82.8 (71.8 to 90.1) | 3.7 (0.7 to 18.3) | 86.4 (76.1 to 92.7) |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12 | 4.96 ± 4.97 | -43.49 ± 4.46 | 11.27 ± 4.37 | -29.16 ± 3.58 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lp(a) at Week 12 | 1.87 ± 5.21 | -42.83 ± 4.60 | 14.53 ± 5.64 | -23.73 ± 4.18 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12 | 5.23 ± 4.77 | -9.86 ± 4.19 | 3.03 ± 4.85 | -16.64 ± 4.09 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | 10.01 ± 5.63 | -7.55 ± 4.73 | 0.69 ± 5.56 | -11.66 ± 4.37 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12 | 1.01 ± 2.65 | 9.45 ± 2.35 | 1.86 ± 2.60 | 8.66 ± 2.18 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 | 1.95 ± 2.88 | 9.89 ± 2.49 | 0.95 ± 2.97 | 7.12 ± 2.33 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12 | 7.08 ± 5.32 | -15.88 ± 4.73 | 4.95 ± 4.97 | -22.87 ± 4.21 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.
| percent change | Placebo Q2W | Evolocumab 140 mg Q2W | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Percent Change From Baseline in VLDL-C at Week 12 | 11.23 ± 6.12 | -10.55 ± 5.22 | 1.72 ± 5.57 | -14.02 ± 4.42 |
Collected over Mortality: from randomization to end of study (EOS) date; median (min, max) duration was 3.22 (0.99, 4.01) months. AEs: from first dose up to last dose + 30 days or EOS date, whichever was earlier; median (min, max) duration was 2.86 (1.02, 3.88) months.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | 0/42 (0%) | 2/41 (4.9%) | 22/41 (53.7%) |
| Placebo QM | 0/41 (0%) | 4/41 (9.8%) | 22/41 (53.7%) |
| Evolocumab 140 mg Q2W | 0/79 (0%) | 6/79 (7.6%) | 45/79 (57%) |
| Evolocumab 420 mg QM | 0/80 (0%) | 1/80 (1.3%) | 42/80 (52.5%) |
| Event | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Angina pectorisCardiac disorders | 0/41 | 1/41 | 0/79 | 0/80 |
| GoitreEndocrine disorders | 0/41 | 1/41 | 0/79 | 0/80 |
| PeriarthritisMusculoskeletal and connective tissue disorders | 1/41 | 0/41 | 0/79 | 0/80 |
| Cerebrovascular accidentNervous system disorders | 0/41 | 1/41 | 0/79 | 0/80 |
| Diabetic nephropathyRenal and urinary disorders | 0/41 | 1/41 | 0/79 | 0/80 |
| HypertensionVascular disorders | 1/41 | 0/41 | 0/79 | 0/80 |
| Acute myocardial infarctionCardiac disorders | 0/41 | 0/41 | 1/79 | 0/80 |
| Cardiac arrestCardiac disorders | 0/41 | 0/41 | 1/79 | 0/80 |
| Cardiogenic shockCardiac disorders | 0/41 | 0/41 | 1/79 | 0/80 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/41 | 0/41 | 1/79 | 0/80 |
| Event | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/41 | 2/41 | 7/79 | 6/80 |
| HypertensionVascular disorders | 1/41 | 3/41 | 6/79 | 4/80 |
| PyrexiaGeneral disorders | 0/41 | 3/41 | 2/79 | 0/80 |
| Protein urine presentInvestigations | 0/41 | 0/41 | 4/79 | 0/80 |
| Sinus bradycardiaCardiac disorders | 2/41 | 0/41 | 1/79 | 0/80 |
| HyperbilirubinaemiaHepatobiliary disorders | 2/41 | 2/41 | 3/79 | 1/80 |
| Urinary tract infectionInfections and infestations | 2/41 | 0/41 | 0/79 | 2/80 |
| Back painMusculoskeletal and connective tissue disorders | 0/41 | 2/41 | 0/79 | 1/80 |
| Blood pressure increasedInvestigations | 0/41 | 0/41 | 3/79 | 0/80 |
| Urinary occult blood positiveInvestigations | 0/41 | 0/41 | 3/79 | 0/80 |
Full Analysis Set: All participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM | Total |
|---|---|---|---|---|---|
| Mean | 57.8 ± 9.8 | 59.4 ± 10.9 | 61.2 ± 10.6 | 60.9 ± 9.8 | 60.2 ± 10.3 |
| Sex: Female, Male(Participants) | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM | Total |
|---|---|---|---|---|---|
| Female | 11 | 10 | 28 | 29 | 78 |
| Male | 30 | 31 | 51 | 51 | 163 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 41 | 41 | 79 | 80 | 241 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM | Total |
|---|---|---|---|---|---|
| Asian | 41 | 41 | 79 | 80 | 241 |
| Stratification Factor: Cardiovascular (CV) Risk(Participants) | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM | Total |
|---|---|---|---|---|---|
| High/Very High CV Risk | 37 | 38 | 73 | 74 | 222 |
| Not High/Very High CV Risk | 4 | 3 | 6 | 6 | 19 |
| Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL) | Placebo Q2W | Placebo QM | Evolocumab 140 mg Q2W | Evolocumab 420 mg QM | Total |
|---|---|---|---|---|---|
| Mean | 120.9 ± 42.2 | 117.1 ± 28.2 | 113.7 ± 37.7 | 115.5 ± 30.1 | 116.1 ± 34.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from May 2019 to primary completion in Apr 2020, 11 months.
Results were first posted in Aug 2021, 1 year 3 months after primary completion. A results delay was requested in Mar 2021.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab